Enzon Pharmaceuticals Inc
ENZN
Market Cap$6.68M
Close$
$0.63
571.8% upside
Current Fair Value
571.8% upsideUndervalued by 571.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.68 Million |
|---|---|
| Enterprise Value | $-37,614,686.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 0.3 |
| Outstanding Shares | 74,215,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.01 |
|---|---|
| PEG | 1.09 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 86.67 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Enzon Pharmaceuticals Inc
CEO: Andrew Rackear Enzon Pharmaceuticals, Inc is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet. Its headquarters is now in Piscataway, New Jersey. The company is a publicly traded company on NASDAQ under the ...